Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events attributed to KGF were typically oral-related or skin-related; mostly mild to moderate with very few serious events; reporting poor and inconsistent, not appropriate to meta-analyse (SoF comments cell,…
16 studies
GRADE not reported
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin probably leads to higher adverse events compared with azole (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Griseofulvin may leads to higher adverse events compared with terbinafine (low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Combination terbinafine plus azole showed no clear difference in adverse events compared with terbinafine monotherapy (low certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Azole showed no clear difference in adverse events compared with terbinafine (moderate certainty).
1 finding from 1 review
Adverse events · participants with confirmed toenail onychomycosis
Terbinafine showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · people with cancer pain
1 finding from 1 review
Intervention not reported
Adverse events · people with cancer pain
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse events · patients with maintenance of medically‐induced remission in Crohn's disease
5‐ASA showed no clear difference in adverse events compared with placebo (low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
It is very uncertain whether budesonide MMX® 6 mg changes adverse events compared with placebo (very low certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with entocort EC 9mg (moderate certainty).
1 finding from 1 review
Adverse events · Adult patients with active ulcerative colitis
Budesonide MMX® 9 mg showed no clear difference in adverse events compared with placebo (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events · adults with food allergy to fruits
1 finding from 1 review
no estimate extracted
Studies not reported
Very low
Adverse effects requiring withdrawal/discontinuation of study medication · People on continuous VKA treatment undergoing minor oral surgery or dental extractions (eligibility included DOACs and all ages; all four…
Antifibrinolytic therapy - locally-applied tranexamic acid (TXA)… showed no clear difference in side effects or other adverse events requiring withdrawal compared with placebo (placebo solution/mouthwash) (moderate certainty).
1 finding from 1 review
Intervention not reported
Adverse events: · adults and children with cystic fibrosis
1 finding from 1 review
no estimate extracted
1 study · 1 participants
Very low
Serious adverse events · IBD patients
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · patients with anaemia
It is very uncertain whether parenteral iron changes serious adverse events compared with oral iron (very low certainty).
1 finding from 1 review
Adverse events: Vomiting · idiopathic steroid‐resistant nephrotic syndrome in children
It is very uncertain whether IV changes adverse events: vomiting compared with oral cyclophosphamide (very low certainty).
1 finding from 1 review